NOVEL ESTROGEN RECEPTOR MUTATIONS AND USES THEREOF
Novel mutant ESR1 molecules and uses are disclosed.
1 - 122 . (canceled)
123 . A method of treating a subject having an Estrogen Receptor positive (ER+) breast cancer, comprising:
detecting in a sample from the subject a mutant estrogen receptor 1 (ESR1) polypeptide or a nucleic acid molecule encoding the mutant ESR1 polypeptide,
wherein the mutant ESR1 polypeptide, or the nucleic acid molecule encoding the ESR1 polypeptide, comprises one or more of:
one or more missense mutations at amino acid position 311, 341, 350, 394, 414, 433, 503, or 538 of the amino acid sequence of SEQ ID NO:2,
a deletion of nucleotides 1046-1051 of SEQ ID NO:1, or
an insertion between amino acid positions 344 and 345 of SEQ ID NO:2; and
administering to the subject an effective amount of a Selective Estrogen Receptor Degrader (SERD), thereby treating the ER + breast cancer in the subject.
124 . The method of claim 123 , wherein the mutant ESR1 polypeptide comprises one or more of:
an aspartate to glycine substitution at amino acid position 538 (D538G) of SEQ ID NO: 2;
a deletion of amino acids Leu-Ala-Asp (LAD) at positions 349-351 of SEQ ID NO:2;
an insertion of a histidine at amino acid position 349 of SEQ ID NO:2;
a threonine to methionine substitution at amino acid position 311 (T311M) of SEQ ID NO: 2;
a serine to leucine substitution at amino acid position 341 (S341L) of SEQ ID NO: 2;
an alanine to glutamate substitution at amino acid position 350 (A350E) of SEQ ID NO: 2;
an arginine to histidine substitution at amino acid position 394 (R394H) of SEQ ID NO:
2;
a glutamine substitution at amino acid position 414 of SEQ ID NO: 2;
a serine to proline substitution at amino acid position 433 (S433P) of SEQ ID NO: 2;
an arginine to tryptophan substitution at amino acid position 503 (R503W) of SEQ ID NO: 2; or
an insertion of a cysteine between amino acid positions 344 and 345 of SEQ ID NO:2.
125 . The method of claim 123 , wherein said subject:
(i) has previously received a treatment with a SERM;
(ii) has failed a first or second line of treatment with a SERM;
(iii) is postmenopausal or premenopausal;
(iv) stops a treatment with a SERM prior to administration of the SERD;
(v) is premenopausal and an oophorectomy is performed on the subject;
or any combination of (i)-(v).
126 . The method of claim 123 , wherein the subject is postmenopausal.
127 . The method of claim 123 , wherein the SERD is fulvestrant.
128 . The method of claim 123 , wherein the SERD is administered in combination with a different therapeutic agent or a different therapeutic modality.
129 . The method of claim 128 , wherein the different therapeutic agent or modality is selected according to a determination of the presence of a mutation other than the mutant ESR1 polypeptide or the nucleic acid molecule encoding the mutant ESR1 polypeptide, and wherein the mutation other than the mutant ESR1 polypeptide or the nucleic acid molecule encoding the mutant ESR1 polypeptide is a HER2 mutation, a p53 mutation, a BRCA mutation, an NF1 mutation, an EGFR/myc mutation, a PIK3CA mutation, a CCND1 mutation, a CDH1 mutation, or any combination thereof.
130 . The method of claim 123 , wherein the detecting step comprises determining the presence of the mutant ESR1 polypeptide or the nucleic acid molecule encoding the mutant ESR1 polypeptide by sequencing.
131 . The method of claim 130 , wherein the sequencing is next-generation sequencing (NGS).
132 . The method of claim 123 , wherein the subject was previously tested for the presence of a mutant ESR1 polypeptide or a nucleic acid molecule encoding the mutant ESR1 polypeptide, wherein the mutant ESR1 polypeptide or the nucleic acid molecule encoding the mutant ESR1 polypeptide was not detected during the previous testing.
133 . The method of claim 123 , wherein the subject was previously tested or is being tested for the presence of a mutant ESR1 polypeptide or a nucleic acid molecule encoding the mutant ESR1 polypeptide at 6-month or one-year intervals.
134 . The method of claim 123 , further comprising generating a personalized cancer treatment report, by:
obtaining the sample from the subject,
detecting the mutant ESR1 polypeptide or the nucleic acid molecule encoding the mutant ESR1 polypeptide in the sample, and
selecting a treatment based on the ESR1 mutation detected.
135 . The method of claim 123 , further comprising:
(i) identifying, selecting, or obtaining information or knowledge that the subject has participated in a clinical trial or has been treated for cancer; and
(ii) acquiring genotype information that identifies a mutant ESR1 polypeptide or a nucleic acid molecule encoding the mutant ESR1 polypeptide as being in the subject,
wherein the presence of the mutant ESR1 polypeptide or the nucleic acid molecule encoding the mutant ESR1 polypeptide identifies the subject as having an increased risk for, or having, a cancer associated with the mutant ESR1 polypeptide or the nucleic acid molecule encoding the mutant ESR1 polypeptide.
136 . The method of claim 123 , wherein the ER+ breast cancer is metastatic or advanced ER+ breast cancer.
137 . The method of claim 123 , wherein the ER+ breast cancer is a localized ER+ breast cancer.
138 . The method of claim 123 , further comprising, prior to the detecting, acquiring the sample from the subject.
139 . The method of claim 123 , wherein the sample comprises one or more of: a tissue biopsy, whole blood, serum, plasma, buccal scrape, sputum, saliva, cerebrospinal fluid, urine, stool, circulating tumor cells, circulating nucleic acids, or bone marrow.
140 . The method of claim 123 , wherein the sample comprises a tumor biopsy, circulating tumor cell, or circulating nucleic acids.
141 . The method of claim 123 , further comprising identifying the subject as having breast cancer with ER+ status.
142 . The method of claim 141 , wherein the subject is identified as having ER+ breast cancer by immunohistochemistry.